The resurrected Babcock and Wilcox is developing a 200kW AHR called the Medical Isotope Production System to produce Mo-99 and other isotopes. As described by the September 2008 IAEA report Homogeneous Aqueous Solution Nuclear Reactors for the Production of Mo-99 and other Short Lived Radioisotopes:
Current concepts under consideration include a 200 kW reactor, capable of producing approximately 1,100 six day Ci/week of 99Mo and other useful isotopes. An existing containment structure formerly housing a pool type research reactor at the BWXT facility in Lynchburg, VA, is under consideration for an initial commercial facility (Figure 1). The reactor would contain approximately 150 L of LEU solution and would operate at approximately 80˚C and atmospheric pressure. A new separation/purification facility is envisioned with hot cell capacity for the several separation/purification/packaging and shipping functions as well as a waste management facility.
The recently-published Medical Isotope Production Without Highly Enriched Uranium has more details. B&W hopes to field the MIPS 5-6 years after a radiopharmaceutical partner is identified, but faces a bevy of challenges related not only to the conceptual design of the reactor, but also to the fact that NRC regulations are ambiguous as to the classification of an AHR and its waste stream. They hope to convert an existing containment structure in Lynchburg, Virginia from an old pool-type reactor to house the first unit. B&W is hiring a lead project engineer to manage the development effort. Anyone out there with experience in liquid-fueled reactor design?
UPDATE: B&W has announced a partnership with radiopharmaceutical manufacturer Covidien to develop the MIPS.